pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ebanga
drug
save

ansuvimab

Marketedupdated 3mo ago
by Ridgeback Biotherapeutics LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval20 co-mentions · 5 sources
  • drugEBANGA20 co-mentions · 5 sources
  • companyRidgeback Biotherapeutics LLC10 co-mentions · 5 sources

all catalysts(5)

approval · 5
Dec 21, 2020
approval
6y ago
EBANGA (ANSUVIMAB-ZYKL) — FDA approval
ansuvimab
→
Dec 7, 2021
approval
5y ago
EBANGA (ANSUVIMAB-ZYKL) — FDA approval
ansuvimab
→
May 19, 2022
approval
4y ago
EBANGA (ANSUVIMAB-ZYKL) — FDA approval
ansuvimab
→
Dec 26, 2024
approval
2y ago
EBANGA (ANSUVIMAB-ZYKL) — FDA approval
ansuvimab
→
Feb 18, 2026
approval
6mo ago
EBANGA (ANSUVIMAB-ZYKL) — FDA approval
ansuvimab
→

Trials studying ansuvimab

  • —Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEPavailable

News(1)

  • Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuring
    Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”
    fiercebiotech · 9d ago
brand
Ebanga
generic
ansuvimab-zykl
indication
Ebolavirus Infections (Ebola Hemorrhagic Fever)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?